82769-01-5

Basic information

• Product Name: (1R,4S)-1-Methyl-4-(prop-1-en-2-yl)cyclohex-2-enol
• Synonyms: (1R,4S)-1-Methyl-4-(prop-1-en-2-yl)cyclohex-2-enol;(1R,4S)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-en-1-ol;(-)-Menthadienol;2-Cyclohexen-1-ol, 1-methyl-4-(1-methylethenyl)-, (1R-cis)-
• CAS NO: 82769-01-5
• Molecular Formula: C₁₀H₁₆O
• Molecular Weight: 152.23344
• Mol File: 82769-01-5.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 216.9±40.0 °C(Predicted)
• Appearance: /
• Density: 0.947±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
• PKA: 14.66±0.40(Predicted)
• Stability: Light Sensitive
• CAS DataBase Reference: (1R,4S)-1-Methyl-4-(prop-1-en-2-yl)cyclohex-2-enol(CAS DataBase Reference)
• NIST Chemistry Reference: (1R,4S)-1-Methyl-4-(prop-1-en-2-yl)cyclohex-2-enol(82769-01-5)
• EPA Substance Registry System: (1R,4S)-1-Methyl-4-(prop-1-en-2-yl)cyclohex-2-enol(82769-01-5)

Safety Data

• Hazardous Substances Data: 82769-01-5(Hazardous Substances Data)

Usage

Uses

(1R,4S)-1-Methyl-4-(prop-1-en-2-yl)cyclohex-2-en-1-ol acts as a reagent in the synthesis of cannabinoids that functions as pharmaceutical active agents for some dosage forms, and also used as a reagent in the preparation of some pharmaceutical intermediates.

Upstream product

• 74756-09-5 1α-hydroxy-2β-phenylseleno-trans-p-menth-8-ene 
• 1195-92-2 Limonene oxide 
• 138-86-3 limonene. 
• 106-24-1 Geraniol 
• 106-25-2 Nerol 
• 5989-27-5 D-limonene 
• 1686-14-2 α-pinene epoxide 

Downstream Products

• 16750-82-6 (S)-isopiperitenone 
• 16849-50-6 tetrahydrocannabinol 
• 14132-18-4 6,6,9-Trimethyl-3-pentyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-1-ol 
• 71697-77-3 6β-(2'-hydroxyisopropyl)-3-methyl-2-cyclohexenone 
• 83217-89-4 4(15)-eudesmene-1β,11-diol 
• 6252-34-2 6-(1'-hydroxyisopropyl)-3-methyl-2-cyclohexenol 
• 68754-14-3 1-acetoxy-trans-p-mentha-2,8-diene 
• 6909-05-3 iso-Δ⁸-tetrahydrocannabinol 
• 3556-78-3 cannabidiol 
• 43009-38-7 (6aS,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol 
• 536697-79-7 abn-cannabidiol 

Relevant articles and documents

Activated vs. pyrolytic carbon as support matrix for chemical functionalization: Efficient heterogeneous non-heme Mn(II) catalysts for alkene oxidation with H2O2

Two types of heterogeneous catalytic materials, MnII-L3imid@Cox and MnII-L3imid@PCox, have been synthesized and compared by covalent grafting of a catalytically active [MnII-L3imid] complex on the surface of an oxidized activated carbon (Cox) and an oxidized pyrolytic carbon from recycled-tire char (PCox). Both hybrids are non-porous bearing graphitic layers intermixed with disordered sp2/sp3 carbon units. Raman spectra show that (ID/IG)activatedcarbon > (ID/IG)pyrolyticcarbon revealing that oxidized activated carbon(Cox) is less graphitized than oxidized pyrolytic carbon (PCox). The MnII-L3imid@Cox and MnII-L3imid@PCox catalysts were evaluated for alkene oxidation with H2O2 in the presence of CH3COONH4. Both showed high selectivity towards epoxides and comparing the achieved yields and TONs, they appear equivalent. However, MnII-L3imid@PCox catalyst is kinetically faster than the MnII-L3imid@Cox (accomplishing the catalytic runs in 1.5 h vs. 5 h). Thus, despite the similarity in TONs MnII-L3imid@PCox achieved extremely higher TOFs vs. MnII-L3imid@Cox. Intriguingly, in terms of recyclability, MnII-L3imid@Cox could be reused for a 2th run showing a ～20% loss of its catalytic activity, while MnII-L3imid@PCox practically no recyclable. This phenomenon is discussed in a mechanistic context; interlinking oxidative destruction of the Mn-complex with high TOFs for MnII-L3imid@PCox, while the low-TOFs of MnII-L3imid@Cox are preventive for the oxidative destruction of the Mn-complex.

Influence of the Br?nsted and Lewis acid sites on the catalytic activity and selectivity of Fe/MCM-41 system

The system Fe2O3/MCM-41, with high iron dispersion, was synthesized in order to introduce Lewis acid sites into the MCM-41 structure. Two calcination atmospheres (inert and oxidant) were used to produce iron nanoclusters with different structural properties. Besides, a silylation treatment was realized on both solids with the aim of neutralizing the Br?nsted acidity associated with the MCM-41 silanol groups. The samples were characterized by atomic absorption spectroscopy, X-ray diffraction at low angles, N2 adsorption, temperature-programmed reduction, Fourier transform infrared spectroscopy, nuclear magnetic resonance of 29Si, and M?ssbauer spectroscopy. The influence of the structural changes of the nanoclusters and the effect of the simultaneous presence of Lewis and Br?nsted acid sites were evaluated studying the product distribution from the α-pinene oxide isomerization reaction. It was determined that the Br?nsted acidity of the Fe/MCM-41 system has not the sufficient acid strength to modify the product distribution which is mainly governed by the Lewis sites.

Abnormal Cannabidiols as agents for lowering intraocular pressure

The present invention provides a method of treating glaucoma or ocular hypertension which comprises applying to the eye of a person in need thereof an amount sufficient to treat glaucoma or ocular hypertension of a compound of formula I wherein Y, Q, Z, R, R1 and R2 are as defined in the specification. The present invention further comprises pharmaceutical compositions, e.g. ophthalmic compositions, including said compound of formula I.